Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma
- 29 July 2015
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 46 (4) , 312-319
Abstract
Aim: For intermediate hepatocellular carcinoma (HCC), transcatheter arterial chemoembolization (TACE) therapy is recommended in the guidelines as a monotherapy, although TACE is a non‐curative therapy. The aims of the present study were to evaluate the efficacy of adding radiofrequency ablation (RFA) to TACE in patients with intermediate HCC, and to identify the factors that were associated with favorable survival in these patients.Methods: Fifty‐nine patients with intermediate HCC were enrolled in this retrospective study. Thirty‐nine patients were treated with TACE alone and 20 patients were treated with additional RFA after TACE.Results: The recurrence‐free survival rates at 0.5, 1 and 2 years for the additional RFA group were 32%, 19% and 13%, respectively, and these were significantly higher than those of the TACE group (8%, 3% and 0%, respectively; log–rank test, P = 0.001). The cumulative survival rates of the additional RFA group were significantly higher than those of the TACE group (log–rank test, P = 0.002), although this significant difference was not found in the subgroup of treatment naive patients because of small sample size. Multivariate analysis indicated male sex, lower total bilirubin, lower α‐fetoprotein, lower des‐γ‐carboxyprothrombin, newly recurrent HCC nodules within the last 12 months and additional RFA as independent factors that were significantly associated with favorable overall survival.Conclusion: Additional RFA of nodules insufficiently treated by TACE is effective therapy for obtaining favorable disease‐free survival in patients with intermediate HCC, and leads to better overall survival particularly in recurrent patients.Keywords
Funding Information
- Japanese Ministry of Education, Culture, Sports, Science and Technology
- Japanese Ministry of Health, Labor and Welfare
This publication has 31 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated VersionDigestive Diseases, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Implication of Frequent Local Ablation Therapy for Intrahepatic Recurrence in Prolonged Survival of Patients With Hepatocellular Carcinoma Undergoing Hepatic ResectionAnnals of Surgery, 2006
- Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular CarcinomaAnnals of Surgery, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 YearsAnnals of Surgery, 2001